News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
839,381 Results
Type
Article (86144)
Company Profile (649)
Press Release (752588)
Multimedia
Podcasts (129)
Webinars (14)
Section
Business (232244)
Career Advice (4125)
Deals (39713)
Drug Delivery (126)
Drug Development (90809)
Employer Resources (198)
FDA (18006)
Job Trends (17327)
News (395609)
Policy (39679)
Tag
Academia (2992)
Academic (1)
Accelerated approval (6)
Adcomms (25)
Allergies (82)
Alliances (56670)
ALS (80)
Alzheimer's disease (1473)
Antibody-drug conjugate (ADC) (144)
Approvals (17994)
Artificial intelligence (227)
Autoimmune disease (27)
Automation (12)
Bankruptcy (403)
Best Places to Work (12512)
BIOSECURE Act (22)
Biosimilars (119)
Biotechnology (447)
Bladder cancer (77)
Brain cancer (26)
Breast cancer (231)
Cancer (2052)
Cardiovascular disease (143)
Career advice (3532)
Career pathing (34)
CAR-T (163)
Cell therapy (452)
Cervical cancer (17)
Clinical research (72867)
Collaboration (789)
Company closure (1)
Compensation (454)
Complete response letters (28)
COVID-19 (2832)
CRISPR (44)
C-suite (226)
Cystic fibrosis (99)
Data (1889)
Decentralized trials (2)
Denatured (45)
Depression (39)
Diabetes (189)
Diagnostics (6762)
Digital health (9)
Diversity (9)
Diversity, equity & inclusion (48)
Drug discovery (118)
Drug pricing (96)
Drug shortages (17)
Duchenne muscular dystrophy (82)
Earnings (95433)
Editorial (40)
Employer branding (25)
Employer resources (167)
Events (128624)
Executive appointments (623)
FDA (18979)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (651)
Gene editing (100)
Generative AI (22)
Gene therapy (321)
GLP-1 (739)
Government (5112)
Grass and pollen (4)
Guidances (47)
Healthcare (20744)
Huntington's disease (25)
IgA nephropathy (29)
Immunology and inflammation (129)
Indications (25)
Infectious disease (2949)
Inflammatory bowel disease (151)
Inflation Reduction Act (11)
Influenza (44)
Intellectual property (86)
Interviews (812)
IPO (17695)
IRA (38)
Job creations (5186)
Job search strategy (2861)
Kidney cancer (11)
Labor market (41)
Layoffs (545)
Leadership (22)
Legal (10058)
Liver cancer (72)
Lung cancer (295)
Lymphoma (139)
Machine learning (6)
Management (65)
Manufacturing (292)
MASH (70)
Medical device (14302)
Medtech (14307)
Mergers & acquisitions (22285)
Metabolic disorders (601)
Multiple sclerosis (79)
NASH (22)
Neurodegenerative disease (102)
Neuropsychiatric disorders (24)
Neuroscience (1981)
NextGen: Class of 2025 (7666)
Non-profit (5059)
Now hiring (40)
Obesity (322)
Opinion (271)
Ovarian cancer (70)
Pain (71)
Pancreatic cancer (63)
Parkinson's disease (133)
Partnered (19)
Patents (199)
Patient recruitment (96)
Peanut (48)
People (64919)
Pharmaceutical (131)
Pharmacy benefit managers (13)
Phase I (22516)
Phase II (31682)
Phase III (23816)
Pipeline (1048)
Policy (145)
Postmarket research (3542)
Preclinical (10151)
Press Release (72)
Prostate cancer (90)
Psychedelics (34)
Radiopharmaceuticals (251)
Rare diseases (361)
Real estate (7384)
Recruiting (75)
Regulatory (26457)
Reports (55)
Research institute (2647)
Resumes & cover letters (649)
Rett syndrome (2)
RNA editing (5)
RSV (34)
Schizophrenia (71)
Series A (126)
Series B (72)
Service/supplier (25)
Sickle cell disease (46)
Special edition (18)
Spinal muscular atrophy (164)
Sponsored (34)
Startups (4286)
State (2)
Stomach cancer (11)
Supply chain (51)
Tariffs (40)
The Weekly (82)
Vaccines (743)
Venture capitalists (41)
Weight loss (230)
Women's health (37)
Worklife (20)
Date
Last 7 days (735)
Last 30 days (2041)
Last 365 days (28742)
2025 (8989)
2024 (34070)
2023 (42568)
2022 (53928)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37191)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1265)
Alabama (54)
Alaska (6)
Arizona (246)
Arkansas (8)
Asia (49861)
Australia (8797)
California (5382)
Canada (1591)
China (501)
Colorado (167)
Connecticut (218)
Delaware (133)
Europe (114139)
Florida (672)
Georgia (147)
Hawaii (1)
Idaho (64)
Illinois (449)
India (25)
Indiana (272)
Iowa (10)
Japan (138)
Kansas (111)
Kentucky (16)
Louisiana (8)
Maine (58)
Maryland (847)
Massachusetts (4236)
Michigan (186)
Minnesota (314)
Mississippi (1)
Missouri (53)
Montana (24)
Nebraska (26)
Nevada (54)
New Hampshire (50)
New Jersey (1537)
New Mexico (27)
New York (1524)
North Carolina (1011)
North Dakota (8)
Northern California (2353)
Ohio (164)
Oklahoma (13)
Oregon (45)
Pennsylvania (1141)
Puerto Rico (12)
Rhode Island (24)
South America (1648)
South Carolina (4)
South Dakota (1)
Southern California (2010)
Tennessee (31)
Texas (706)
United States (20160)
Utah (115)
Virginia (104)
Washington D.C. (45)
Washington State (517)
West Virginia (1)
Wisconsin (41)
839,381 Results for "bit bio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
bit.bio Launches ioAstrocytes, Advancing How Scientists Can Model the Human Brain
bit.bio, the company coding human cells for novel cures and a pioneer in the field of synthetic biology, announces the launch of ioAstrocytes.
June 20, 2024
·
5 min read
Press Releases
bit.bio Launches ioTracker Cells Range at SLAS 2025, Adding New Visualisation Functionality to Human iPSC-derived Cell Types
January 27, 2025
·
5 min read
Business
bit.bio Announced as Inaugural Partner of Ginkgo Bioworks’ New Technology Network
bit.bio, the company coding human cells for novel cures, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced bit.bio as an inaugural partner of the Ginkgo Technology Network.
February 28, 2024
·
9 min read
Press Releases
bit.bio Wins Landmark Patent Defence for Groundbreaking opti-ox™ Cell Programming Technology
October 16, 2024
·
6 min read
Press Releases
bit.bio to Unveil iPSC Advancements and ioCells Toolkit at Society for Neuroscience 2024 Annual Conference
September 30, 2024
·
5 min read
Neuroscience
GSK Dives Deeper Into Neuro With $2.5B+ ABL Bio Pact
GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.
April 7, 2025
·
2 min read
·
Tristan Manalac
Genetown
bit.bio Announces First Project Within Multi-Year Collaboration Agreement with The Michael J. Fox Foundation (MJFF) to Generate Human Cell Products for Research and Drug Discovery in Parkinson’s disease
bit.bio, the company coding human cells for novel cures, announces the first project within a multi-year collaboration agreement with The Michael J. Fox Foundation for Parkinson’s Research to prioritise the development and delivery of a range of human cell products relevant to Parkinson’s disease.
March 5, 2024
·
5 min read
bit.bio further expands ioCells™️ range with early access launch of ioMotor Neurons™️ for research and drug discovery in diseases such as amyotrophic lateral sclerosis (ALS)
bit.bio, the company coding human cells for novel cures, has launched ioMotor Neurons as its 12th ioCells product this year.
December 6, 2023
·
5 min read
Business
bit.bio Expands Board of Directors With Appointment of Distinguished Investor, Philanthropist, and Scientist
Weslie Janeway joins bit.bio board.
May 11, 2023
·
4 min read
Immunology and inflammation
Hillstar Bio Nets $67M Series A to Advance Autoimmune and Arthritis Pipeline
Led by alums from Takeda and Boston Pharmaceuticals, Hillstar Bio is working on treatments that remove harmful immune cells to relieve disease.
March 25, 2025
·
2 min read
·
Dan Samorodnitsky
1 of 83,939
Next
